tbuckley/cabot-search huggingface dataset:
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Authors: T E Witzig, C B Reeder, B R LaPlant, M Gupta, P B Johnston, I N Micallef, L F Porrata, S M Ansell, J P Colgan, E D Jacobsen, I M Ghobrial, T M Habermann
Journal: Leukemia (2010)

The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). The goal of this trial was to learn the antitumor activity and toxicity of single-agent everolimus in patients with relapsed/refractory aggressive NHL. Patients received everolimus 10 mg PO daily. Response was assessed after two and six cycles, and then every three cycles until progression. A total of 77 patients with a median age of 70 years were enrolled. Patients had received a median of three previous therapies and 32% had undergone previous transplant. The overall response rate (ORR) was 30% (95% confidence interval: 20–41%), with 20 patients achieving a partial remission and 3 a complete remission unconfirmed. The ORR in diffuse large B cell was 30% (14/47), 32% (6/19) in mantle cell and 38% (3/8) in follicular grade 3. The median duration of response was 5.7 months. Grade 3 or 4 anemia, neutropenia and thrombocytopenia occurred in 14, 18 and 38% of patients, respectively. Everolimus has single-agent activity in relapsed/refractory aggressive NHL and provides proof-of-concept that targeting the mTOR pathway is clinically relevant.
Midline Catheterization in Hospitalized Patients
Authors: Timothy C. Evans
Journal: Annals of Internal Medicine (1996)

Letters15 October 1996Midline Catheterization in Hospitalized PatientsTimothy C. Evans, MD, PhDTimothy C. Evans, MD, PhDUniversity of Washington, Seattle, WA 98105Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-125-8-199610150-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In their recent report, Mermel and colleagues [1] present useful evidence of low infection rates associated with the use of the Landmark midline catheter. Their observations are strengthened by the consecutive patient enrollment design of the study but are weakened by the small number of catheters and patients available for study—only 140 of the 251 catheters inserted and only 130 of the 238 patients originally enrolled. Nevertheless, the evidence of low risk for infection is persuasive.Mermel and colleagues further reported information on adverse reactions that occurred during catheter insertion in two patients during the study and ...REFERENCE1. Mermel LA, Parenteau S, Tow SM. The risk of midline catheterization in hospitalized patients. A prospective study. Ann Intern Med. 1995; 123:841-4. Google Scholar Author, Article, and Disclosure InformationAuthors: Timothy C. Evans, MD, PhDAffiliations: University of Washington, Seattle, WA 98105 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRe‐evaluating expanding intravenous catheters in medical practice 15 October 1996Volume 125, Issue 8Page: 695-696KeywordsAdverse reactionsCatheterizationCathetersInformation storage and retrievalProspective studiesSafetyStatistical data ePublished: 15 August 2000 Issue Published: 15 October 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Closer to a Cure for the Common Cold?
Authors: Kenneth McIntosh
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Restitution Properties During Ventricular Fibrillation in the In Situ Swine Heart
Authors: Jian Huang, Xiaohong Zhou, William M. Smith, Raymond E. Ideker
Journal: Circulation (2004)

Background— Although restitution has been hypothesized to determine action potential duration (APD) during ventricular fibrillation (VF), cardiac memory may also be important. Methods and Results— Transmembrane recordings were made with a floating microelectrode from the anterior right ventricular wall in 6 pigs during up to 60 seconds of VF. The recordings were divided into 5-second intervals, and APD 60 and the diastolic interval (DI) were calculated for each activation cycle throughout each interval. Stepwise linear regression was used to determine how well each APD 60 [APD 60 (n)] was predicted by the 4 previous DIs (n−1, n−2, n−3, n−4) and the 3 previous APD 60 s (n−1, n−2, n−3). A mean±SD of 3±1.5 of the variables entered the regression equation. DI(n−1) (70% of intervals) and APD 60 (n−1) (71% of intervals) appeared most frequently in the regression equations and were the first or second variables entered during the stepwise regression in 87% and 76% of the intervals in which they were present, respectively. The coefficients of DI(n−1) and APD 60 (n−1) were positive 89% and 98% of the time, respectively. R 2 of the regression for all entered variables during all intervals was 0.39±0.05. Conclusions— The high incidence and positive coefficient of DI(n−1) indicate that restitution is important in determining APD during VF, whereas the similarly high incidence and positive coefficient of APD(n−1) indicate that cardiac memory is equally important. The finding that the regression equation accounts for only 39% of the variability of APD indicates that factors other than restitution and memory are also important in determining APD during VF.
Agreement for Detecting Glaucoma Progression with the GDx Guided Progression Analysis, Automated Perimetry, and Optic Disc Photography
Authors: Luciana M. Alencar, Linda M. Zangwill, Robert N. Weinreb, Christopher Bowd, Gianmarco Vizzeri, Pamela A. Sample, Remo Susanna, Felipe A. Medeiros
Journal: Ophthalmology (2009)
THU0466 Pilot Trial of Tocilizumab for Refractory Patients with Adult Onset Still’s Disease
Authors: J. J. Kim, K. S. Na, T. H. Kim, D. H. Yoo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Adult onset Still's disease (AOSD) is a systemic inflammatory disorder with unknown etiology. As therapeutic agents, traditional disease modifying anti-rheumatic drugs (DMARDs) or biological agents are suggested for patients unresponsive to corticosteroid. Among important cytokines for the AOSD pathogenesis, IL-6 plays a pivotal role. Several case reports have suggested that tocilizumab, a humanized anti-interleukin (IL)-6 receptor antibody was effective for intractable AOSD. <h3>Objectives</h3> Here, we described the clinical course of refractory Korean patients treated with tocilizumab therapy. <h3>Methods</h3> The 8 patients who were refractory to DMARDs and/or etarnecept or dependent to corticosteroid were enrolled for tocilizumab therapy after informed contents. Tocilizumab at 8mg/kg was administered every 4 weeks. <h3>Results</h3> Six females and 2 males were treated with tocilizumab. The mean age was 33.8 (26-47) years old. The frequency of tocilizumab therapy was an average of 6.3 (2-13) times. Almost patients showed complete (50.0%) or partial (37.5%) response to tocilizumab therapy except one patient (Table 1). The clinical symptoms improved in 4 weeks (mean), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) improved in 6.3 weeks, respectively. Serum ferritin, IL-18 and IL-6 levels slowly improved within 9.3 weeks, 12.5 weeks and 9.3 weeks, respectively. Three patients discontinued tocilizumab therapy although they showed improvement of clinical symptoms; because of severe headache and chest discomfort at 12 weeks, neutropenia at 8 weeks, and severe hepatotoxicity at 8 weeks, respectively. Other adverse events such as mild dizziness, hair loss, weight gain and transient leucopenia were observed and those were tolerable during follow-up. <h3>Image/graph</h3> <h3>Conclusions</h3> Tocilizumab could be a new therapeutic option for AOSD patients refractory to conventional therapy. However, further clinical trials for efficacy and safety of tocilizumab in patients with AOSD are needed. <h3>Disclosure of Interest</h3> None Declared
Work of mental health review tribunals is increasing faster than detentions
Authors: G E Langley
Journal: BMJ (1999)

EDITOR—Wall et al provide a helpful outline of the significant increase in all psychiatric admissions and in those admitted under the Mental Health Act 1983.1 They mention, but do not document, the effect of these trends on mental health review tribunals.

My study shows that the rate of appeals to, and hearings by, …
The Second Pan-American Medical Congress.
Authors: David Cerna
Journal: JAMA (1896)

<h3>A Reply to Reflections upon the Mexicans as Physicians and as a Race.</h3> Galveston, Texas, May 16,1896. <h3>To the Editor:</h3> —The approaching meeting at the City of Mexico of the second Pan-American Medical Congress, and the appeal of our most efficient Secretary General, Dr. Charles A. L. Reed, to attend it, have aroused in me a variety of feelings impossible to describe at this moment. Dr. Reed has stated: " The enthusiasm with which not only the medical profession, but the government of Mexico has taken hold of the proposed meeting, guarantees its success. The generous patronage which the Washington meeting enjoyed from our Mexican<i>confrères</i>places upon us a pleasant obligation to reciprocate." Would that the whole medical fraternity of this country entertained sentiments similar to those expressed by Dr. Reed. But there are exceptions to be deplored, exceptions that tend to delay at least the unity of the profession
On Boxing and Liberty
Authors: Russel H. Patterson
Journal: JAMA (1986)

SHOULD a sport as brutal as boxing be allowed to exist in civilized society? Is a ban on boxing an excessive restraint of individual freedom? We perhaps could all agree that there should exist a certain minimal area of personal freedom that must not be violated or else the individual will be so confined that he is unable to develop his individuality even to the slightest degree. This means that a boundary or frontier must be defined between private life and public authority. The debate is on where that line should be drawn.<sup>1</sup> John Stuart Mill wrote in his essay, "On Liberty," that there was only one circumstance under which society was entitled to use physical force, legal penalties, or moral coercion. He wrote: That the only principle that is the sole end for which mankind are warranted, individually or collectively, in interfering with the liberty of action of
Obesity as a Predictor of Poor Antibody Response to Hepatitis B Plasma Vaccine
Authors: David J. Weber, William A. Rutala, Gregory P. Samsa, Jane E. Santimaw, Stanley M. Lemon
Journal: JAMA (1985)

Factors associated with lack of antibody response to the hepatitis B virus plasma vaccine were retrospectively evaluated by means of a logistic regression in 194 previously seronegative staff members of a community hospital. All subjects had received three doses of vaccine by intramuscular buttock injection using a 1-in, 23-gauge needle. Overall, only 55.7% of subjects developed detectable antibody to hepatitis B surface antigen in serum after immunization. The weight-height index served as a surrogate measure of obesity. Predictors of poor immunogenic response to hepatitis B vaccine included higher weight-height index, older age, and vaccine batch. Sex, race, timing of vaccine doses, and timing of postimmunization determination of antibody to hepatitis B surface antigen were not predictors of vaccine efficacy.
Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes
Authors: Shubham Shrivastava, Amit Raychoudhuri, Robert Steele, Ranjit Ray, Ratna B. Ray
Journal: Hepatology (2010)

The role of autophagy in disease pathogenesis following viral infection is beginning to be elucidated. We have previously reported that hepatitis C virus (HCV) infection in hepatocytes induces autophagy. However, the biological significance of HCV-induced autophagy has not been clarified. Autophagy has recently been identified as a novel component of the innate immune system against viral infection. In this study, we found that knockdown of autophagy-related protein beclin 1 (BCN1) or autophagy-related protein 7 (ATG7) in immortalized human hepatocytes (IHHs) inhibited HCV growth. BCN1- or ATG7-knockdown IHHs, when they were infected with HCV, exhibited increased expression of interferon-β, 2′,5′-oligoadenylate synthetase 1, interferon-α, and interferon-α–inducible protein 27 messenger RNAs of the interferon signaling pathways in comparison with infected control IHHs. A subsequent study demonstrated that HCV infection in autophagy-impaired IHHs displayed caspase activation, poly(adenosine diphosphate ribose) polymerase cleavage, and apoptotic cell death. Conclusion: The disruption of autophagy machinery in HCV-infected hepatocytes activates the interferon signaling pathway and induces apoptosis. Together, these results suggest that HCV-induced autophagy impairs the innate immune response. (HEPATOLOGY 2011;53:406-414)
Razoxane: a review of 6 years' therapy in psoriasis
Authors: J.J. HORTON, R.S. WELLS
Journal: British Journal of Dermatology (1983)

Razoxane is an effective drug in the systemic treatment of psoriasis, with an initial response rate of 97%. After continuous therapy for up to 6 years we found that 72% of patients remained on the drug with a good therapeutic benefit. We found it to be useful in all forms of cutaneous psoriasis and psoriatic arthropathy. It does not appear to produce hepatic damage and is therefore particularly useful in patients intolerant of methotrexate. We use it as our drug of first choice in the systemic treatment of psoriasis, but it does have several well-recognized side-effects which make careful follow-up necessary. Eighteen per cent of patients stopped razoxane because of these side-effects. However, we feel that razoxane has a valuable place in the systemic treatment of severe psoriasis.
Mebendazole and hydatid disease.
Authors: A Bryceson
Journal: BMJ (1980)

it is a pity that the design was not better.The treatment group received specific and non- specific therapy (exercise therapy and regular supervision from a nurse, with occasional medical review), while the controlled group received neither on leaving hospital.As the non-specific factors were uncontrolled, the conclusion that simple exercise rehabilitation is of benefit is invalid.
Transient Receptor Potential Vanilloid Type 2 (TRPV2) Expression in Normal Urothelium and in Urothelial Carcinoma of Human Bladder: Correlation with the Pathologic Stage
Authors: Sara Caprodossi, Roberta Lucciarini, Consuelo Amantini, Massimo Nabissi, Giacomo Canesin, Patrizia Ballarini, Adriana Di Spilimbergo, Marco Andrea Cardarelli, Lucilla Servi, Gabriele Mammana, Giorgio Santoni
Journal: European Urology (2007)
757-5 Hemodynamic Effects of Synthetic Human Brain Natriuretic Peptide Infusion in Patients with Severe Congestive Heart Failure: A Placebo-controlled, Crossover Trial
Authors: Lee S. Marcus, Douglas Hart, Milton Packer, Madeline Yushak, Norma Medina, Stuart D. Katz
Journal: Journal of the American College of Cardiology (1995)
A decade of skeletal tuberculosis.
Authors: J P Halsey, J S Reeback, C G Barnes
Journal: Annals of the Rheumatic Diseases (1982)

Thirty-eight of 58 patients with skeletal tuberculosis (TB) reviewed were immigrants and 20 were of British indigenous origin. Spinal involvement i 28 cases was less common than involvement of peripheral joints, bones, or tendon sheaths (30 cases). Predisposing factors, including previous TB, were present in 70% of British patients and 31% of immigrants. Follow-up study of 23 cases showed that a complete clinical recovery of the skeletal disease was more likely in immigrants than indigenous cases and also in cases referred to hospital early. Immigrants presented usually within 5 years after arrival in Britain and at a younger age than indigenous cases; a quarter had within 5 sites of infection outside the skeletal system. Skeletal tuberculosis in the indigenous population remains very uncommon, and in half of these cases a history of previous TB was given. The need for continued awareness of skeletal TB is stressed, especially in immigrants, and also the importance of early diagnosis and institution of appropriate therapy.
A CASE OF GAS GANGRENE ASSOCIATED WITH B. OEDEMATIENS
Authors: E. J. Dalyell
Journal: BMJ (1917)

CGAS GANGRENE.IMIEw BrTns 36 adherent to uinderlyings structures.There was miarlked wrist- drop and apparently considerable loss of nmuscular tissue.The iproximal and distal ends of the radial fracture could be readily felt at about a distance of two inches from each other.This was well seen also in the skiagram.Employing strict aseptic precautions, I operated on Novemilber .26th., I took the graft from the tibia, and followed Albee's technique throughotit, except that I used a Hey's saw instead of a motor-driveii circular saw.A lonig curved incisioln was miade on the front of the forearm, well away from the scar.This was completely undermiued, and found to be adherent to the fracture(d ends of the radius, most of the muscular tissue in the proximity of the fracture having beeni destroyed either at the time of the wounid or by subsequent sloughing.Oni com- pletion of the operation the forearm was put up on a splint midway between proiiation anid supiDation.At the end of a week I diessed the wouind for the first time and found tbat, although the slkin incision had healed by first intentioni, part of the original scar tissue about the size of a Ave shilling piece had sioughed, exposinig about du inch of the graft.My first impression was that the operation was doomed to failure.Employing very strict technique, according to Rutherford Morisoni's method, however, I applied "Bipp"I to the sloughinig surface, and renewed the " Bipp " every teln dlays, with the result that the skin wound had healed nine wveeks after operation, and the unioif of the graft to radius was strong.The skiagram showed the graft in.excellent position.The use of "Bipp" after this bone-grafting operation .5vassuggested to mne by the excellent results I had by it in compound comminuted fractures, hernia cerebri, etc.In this connexion I wish to take the opportunity of thlankiug Lieutenant-Colonel Sir Berkeley Moynilian for advising and encouraging me-on one of hlis official visits of inspection at this lhospital-to persevere with " Bipp" in thle treatnmenit of troublesome comnminuted fractures.Also Lieutenant-Colonel Robert Jones
Ikaros DNA-Binding Proteins as Integral Components of B Cell Developmental-Stage-Specific Regulatory Circuits
Authors: Elizabeth C. Thompson, Bradley S. Cobb, Pierangela Sabbattini, Sonja Meixlsperger, Vania Parelho, David Liberg, Benjamin Taylor, Niall Dillon, Katia Georgopoulos, Hassan Jumaa, Stephen T. Smale, Amanda G. Fisher, Matthias Merkenschlager
Journal: Immunity (2007)
Assessing Value in Biomedical Research
Authors: John P. A. Ioannidis, Muin J. Khoury
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 5069: Engineering TIMP-1 for selective MMP inhibition and future use as a protein therapeutic.
Authors: Christine Mehner, Jyotica Batra, Jessica Robinson, Derek C. Radisky, Evette S. Radisky
Journal: Cancer Research (2013)

Abstract Matrix metalloproteinases (MMPs), a family of extracellular matrix degrading proteins, have been found to be upregulated in many human cancers and have been shown to contribute to cancer progression. There have been many aborted attempts to target MMPs therapeutically using small molecule inhibitors; the limited selectivity of most MMP inhibitors may be a major factor contributing to their poor effectiveness. As an alternative to small molecule MMP inhibitors, we are developing new methodology to create selective protein inhibitors of MMPs, based on the scaffold of the natural inhibitor TIMP-1, that may be used as protein therapeutics. Because TIMP-1 has a very short plasma half-life, we have developed methods for PEGylation that extend the plasma half-life to about 24h while preserving MMP inhibitory activity, rendering it more suitable for in vivo applications. We have also generated mutations in TIMP-1 that confer selective binding toward particular MMPs. The targets thus far pursued include MMP-9, MMP-3, and MMP-10, which represent therapeutic targets of interest in breast cancer and lung cancer. In the future, the methods developed here can be used to identify TIMP-1 variants selective toward additional MMPs, which may be of utility in the research and treatment of many human cancers. Citation Format: Christine Mehner, Jyotica Batra, Jessica Robinson, Derek C. Radisky, Evette S. Radisky. Engineering TIMP-1 for selective MMP inhibition and future use as a protein therapeutic. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5069. doi:10.1158/1538-7445.AM2013-5069
A New Device for Better Control of the Polypectomy Snare Wire
Authors: F. S. Salameh
Journal: Endoscopy (2004)

When conducting polypectomy procedures, we noticed that it was difficult to control the direction of the snare wire used during resection - especially in the case of large polyps - since the force applied to open the wire acts only in the forward direction, and there is no means of ensuring that the snare wire will rotate in the same direction as the endoscope. Only the surgeon’s skill can then be used for maneuvering and encircling the polyp.